Treatment before enrollment
| Prior treatment . | SIR + PRE group (n = 37) . | SIR group (n = 36) . | P values . | OR (95% CI) . |
|---|---|---|---|---|
| Total, no. (%)* | 17 (45.9) | 20 (55.6) | .412† | 0.680 (0.270-1.710) |
| Partial resection | 0 (0.0) | 1 (2.8) | N/A | N/A |
| Chest tube | 1 (2.7) | 0 (0.0) | N/A | N/A |
| Sclerotherapy | 3 (8.1) | 2 (5.6) | 1.000‡ | 1.500 (0.236-9.552) |
| Embolization | 1 (2.7) | 2 (5.6) | .615‡ | 0.472 (0.041-5.449) |
| Compression therapy | 3 (8.1) | 1 (2.8) | .615‡ | 3.088 (0.306-31.170) |
| Medical therapy§ | ||||
| Propranolol | 4 (10.8) | 3 (8.3) | 1.000‡ | 1.333 (0.277-6.427) |
| Corticosteroidsǁ | 8 (21.6) | 10 (27.8) | .542† | 0.717 (0.246-2.091) |
| Vincristine | 2 (5.4) | 2 (5.6) | 1.000‡ | 0971 (0.129-7.294) |
| Supportive care treatments¶ | 8 (21.6) | 6 (16.7) | .591† | 1.379 (0.426-4.467) |
| Prior treatment . | SIR + PRE group (n = 37) . | SIR group (n = 36) . | P values . | OR (95% CI) . |
|---|---|---|---|---|
| Total, no. (%)* | 17 (45.9) | 20 (55.6) | .412† | 0.680 (0.270-1.710) |
| Partial resection | 0 (0.0) | 1 (2.8) | N/A | N/A |
| Chest tube | 1 (2.7) | 0 (0.0) | N/A | N/A |
| Sclerotherapy | 3 (8.1) | 2 (5.6) | 1.000‡ | 1.500 (0.236-9.552) |
| Embolization | 1 (2.7) | 2 (5.6) | .615‡ | 0.472 (0.041-5.449) |
| Compression therapy | 3 (8.1) | 1 (2.8) | .615‡ | 3.088 (0.306-31.170) |
| Medical therapy§ | ||||
| Propranolol | 4 (10.8) | 3 (8.3) | 1.000‡ | 1.333 (0.277-6.427) |
| Corticosteroidsǁ | 8 (21.6) | 10 (27.8) | .542† | 0.717 (0.246-2.091) |
| Vincristine | 2 (5.4) | 2 (5.6) | 1.000‡ | 0971 (0.129-7.294) |
| Supportive care treatments¶ | 8 (21.6) | 6 (16.7) | .591† | 1.379 (0.426-4.467) |
SIR, sirolimus; PRE, prednisolone; N/A, data not available.
One patient may have received more than 1 treatment regimen.
P value was calculated with χ2 test.
P value was calculated with Fisher's exact test.
All drugs were administered in referring institutions (before referral).
The corticosteroid treatment protocols were variable, including oral prednisolone/prednisone (11 patients), intravenous methylprednisolone (4 patients), intravenous dexamethasone (2 patients), and intralesional injection of triamcinolone and betamethasone (1 patient). The average duration of oral prednisolone/prednisone therapy was 21.3 d (range, 6.0-35.0). The mean duration from previous corticosteroid treatment to trial treatment was 28.7 d (range, 9.0-62.0).
Supportive care treatments included fresh frozen plasma, cryoprecipitate, and packed red blood cells.